The selective protein kinase C β inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway

Journal of Investigative Dermatology

Volumn 126, Issue 7, 2006, Pages 1641-1647

  Querfeld, Christiane ^a   Rizvi, Mujahid A ^a   Kuzel, Timothy M ^a   Guitart, Joan ^a   Rademaker, Alfred ^a   Sabharwal, Simran S ^a   Krett, Nancy L ^a   Rosen, Steven T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; CYTOKINE; ENZASTAURIN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; LIPOCORTIN 5; PHOSPHATIDYLINOSITOL 3 KINASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN KINASE B; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; PROTEIN S6; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL DEATH; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DOWN REGULATION; DRUG EFFECT; EFFECTOR CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

APOPTOSIS; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INDOLES; LYMPHOMA, T-CELL, CUTANEOUS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 33745207996     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700322     Document Type: Article

References (29)

1. Altman A, Isakov N, Baier C (2000) Protein kinase C theta: a new essential superstar on the T-cell stage. Immunol Today 21:567-73
2. Bertolotto C, Maulon L, Filippa N, Baier CG, Auberger P (2000) Protein kinase C theta and epsilon promote T-cell survival by a rsk-dependent phosphorylation and inactivation of BAD. J Biol Chem 275:37246-50
3. Boorsma DM, Flier J, Sampat S, Ottevanger C, DeHaan P, Hooft L et al. (1998) Chemokine IP-10 expression in cultured human keratinocytes. Arch Dermatol Res 290:335-41
4. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E et al. (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318-21
5. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL et al. (2003) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer therapy. Leukemia 17:590-603
6. +/- mice. Science 285:2122-5
7. Felli MP, Vacca A, Calce A, Bellavia D, Campese AF, Grillo R et al. (2005) PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia. Oncogene 24:992-1000
8. Fine RA, Kim L, Royce C, Draper D, Haggarty I, Ellinzano H et al. (2005) Results from phase II trial of Enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol 23:115s
9. Gorelik G, Barreiro Arcos ML, Klecha AJ, Cremaschi GA (2002) Differential expression of protein kinase C isoenzymes related to high nitric oxide synthase activity in a T lymphoma cell line. Biochim Biophys Acta 1588:179-88
10. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN et al. (2005) The protein kinase C β-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65:7462-9
11. Hans CP, Weisenburger DD, Greiner TC, Chan WC, Aoun P, Cochran GT et al. (2005) Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 18:1377-84
12. Keyes KA, Mann L, Sherman M, Galbreath E, Schirtzinger L, Ballard D et al. (2004) LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 53: 133-140
13. Khwaja A (1999) Akt is more than just a Bad kinase. Nature 410:3334
14. Krett N, Davies KM, Ayres M, Ma C, Nabhan C, Gandhi V (2004) Rosen ST. 8-Amino-adenosine is a potential therapeutic agent for multiple myeloma. Mol Cancer Ther 3:1411-20
15. Laine J, Kunstle G, Obata T, Sha M, Noguchi M (2000) The protooncogene TCL1 is an AKT kinase coactivator. Mol Cell 6:395-407
16. Laouar A, Glesne D, Huberman E (1999) Involvement of protein kinase C-beta and ceramide in tumor necrosis factor-alpha-induced but not Fas-induced apoptosis of human myeloid leukemia cells. J Bio Chem 274:23526-34
17. Lisowska K, Bryl E, Soroczynska M, Witkowski JM (2003) Modulation of CD40L antigen expression in Jurkat cells: involvement of protein kinase C activity. Folia Histochem Cytobiol 41:233-5
18. Long A, Kelleher D, Lynch S, Volkov Y (2001) Cutting edge: protein kinase C beta expression is critical for export of Il-2 from T cells. J Immunol 167: 636-40
19. Mischak H, Kolch W, Goodnight J, Davidson WF, Rapp U, Rose-John S, Mushinski JF (1991) Expression of protein kinase C genes in hemopoietic cells in cell-type- and B cell-differentiation stage specific. J Immunol 147:3981-7
20. Pap M, Cooper GM (1998) Role of GSK-3 in the PI-3 kinase/Akt survival pathway. J Cell Chem 273:19929-32
21. Querfeld C, Guitart J, Kuzel TM, Rosen ST (2003) Primary cutaneous lymphomas: a review with current treatment options. Blood Rev 17:131-42
22. Shankar SL, Krupski M, Parashar B, Okwuaka C, O'Guin K, Mani S et al. (2004) UCN-01 alters phosphorylation of Akt and GSK3β and induces apoptosis in six independent human neuroblastoma cell lines. J Neurochem 90:702
23. Sun Z, Arendt CW, Ellmeier W, Schaefer EM, Sunshine MJ, Gandhi L et al. (2000) PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 404:402-7
24. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul M (2001a) Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts. Clin Cancer Res 7:634-40
25. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul MM (2001b) Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in murine lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts. Cancer Chemother Pharmacol 48:473-80
26. Teicher BA, Menon K, Alvarez E, Shih C, Faul MM (2002) Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts. Invest New Drugs 20:241-51
27. Villalba M, Kasibhatla S, Genestier L, Mahboubi A, Green DR, Altman A (1999) Protein kinase C theta cooperates with calcineurin to induce Fas ligand expression during activation-induced T-cell death. J Immunol 163:5813-9
28. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nature Reviews Cancer 2:489-501
29. Uddin S, Hussain A, Al-Hussein K, Platanias LC, Bhatia KG (2005) Inhibition of phosphatidylinositol 3′-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Clinical Cancer Research 11: 3102-8